Colgate-Palmolive Company
CL
$91.30
-0.33%
Colgate-Palmolive is a leading global consumer goods company specializing in oral care, personal care, home care, and pet nutrition products, operating in over 200 countries. As a dominant player in the household and personal products industry, its namesake oral care line accounts for over 40% of sales, while Hill's Pet Nutrition contributes nearly one-fourth. The current investor narrative centers on the company's resilient growth amid a rotation into defensive stocks, with recent quarterly revenue growth of 8.4% and strong margin performance driving attention.…
CL
Colgate-Palmolive Company
$91.30
Investment Opinion: Should I buy CL Today?
Rating: Hold. Colgate-Palmolive is a high-quality defensive stock with strong margins and accelerating revenue, but its premium valuation limits upside. The analyst consensus is Buy with an average target of $97.65, implying 7.6% upside, which is modest for a stock already trading near its 52-week high.
Supporting Evidence: Revenue growth accelerated to 8.4% YoY in Q1 2026, gross margin is a robust 60.6%, and operating margin of 21.7% is best-in-class. Free cash flow of $3.767B TTM supports a 2.85% dividend yield. However, the trailing P/E of 29.9x is above the 5-year average of ~25x, and the forward P/E of 22.4x still commands a premium to the consumer staples sector median (not provided). The stock offers a 7.6% upside to the average analyst target, but the high target of $110 implies 21.2% upside, while the low target of $85 suggests -6.3% downside.
Risks & Conditions: The Hold rating would upgrade to Buy if the forward P/E compresses below 20x or if revenue growth sustains above 10%. It would downgrade to Sell if gross margins fall below 58% or if the company issues negative guidance. Overall, CL is fairly valued relative to its history and peers, trading at a slight premium justified by its consistent performance and defensive characteristics.
Sign up to view all
CL 12-Month Price Forecast
Colgate-Palmolive is a high-quality defensive stock with strong fundamentals, but its valuation is elevated relative to history, limiting near-term upside. The base case of modest gains to the analyst target is most likely, supported by steady growth and dividends. A bullish upgrade would require sustained revenue acceleration above 8% and margin expansion, while a bearish downgrade would be triggered by margin compression or a recession. The neutral stance reflects the balanced risk/reward, with the stock offering stability rather than explosive growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $97.65 and implied upside of +7.0% versus the current price.
Average Target
$97.65
0 analysts
Implied Upside
+7.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $110
Analyst target range
The stock is covered by 20 analysts, with a consensus recommendation of 'Buy' (mean 2.1 on a 1-5 scale). The average target price is $97.65, implying an upside of 7.6% from the current price of $90.75. The distribution leans bullish, with recent ratings from Citigroup (Buy), Piper Sandler (Overweight), and UBS (Buy) reinforcing positive sentiment. The target range spans from $85.00 (low) to $110.00 (high). The high target of $110 assumes continued growth acceleration and multiple expansion, while the low target of $85 reflects risks from input cost inflation or competitive pressures. The spread of $25 indicates moderate uncertainty. Recent upgrades from Rothschild & Co (Neutral to Buy) and consistent Overweight ratings from JP Morgan and Morgan Stanley suggest growing institutional confidence.
Drowning in data?
Find the real signal!
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth, best-in-class margins, and a defensive low-beta profile that appeals during market uncertainty. The bear case centers on elevated valuation relative to history and underperformance versus the broader market. The single most important tension is whether CL's premium valuation can be sustained by continued earnings growth and margin expansion, or if a reversion to historical multiples will cap returns. Currently, the evidence slightly favors the bull case given the strong fundamental momentum and analyst support, but the stock's low growth relative to the market limits upside potential.
Bullish
- Strong Revenue Growth Acceleration: Revenue grew 8.4% YoY in Q1 2026 to $5.324B, accelerating from 4.9% in Q4 2024, demonstrating strong demand and pricing power across oral care and pet nutrition segments.
- Robust Profitability and Margins: Gross margin of 60.6% and operating margin of 21.7% in Q1 2026 are industry-leading, reflecting efficient cost management and brand strength. Net income of $646M and ROE of 39.5% underscore exceptional shareholder returns.
- Defensive Appeal with Low Beta: With a beta of 0.32, CL offers significant downside protection during market volatility, making it attractive for risk-averse investors seeking stable returns.
- Analyst Consensus Buy and Upside: 20 analysts rate CL a Buy with an average target of $97.65, implying 7.6% upside from $90.75. Recent upgrades from Rothschild & Co and consistent Overweight ratings from JP Morgan and Morgan Stanley reinforce positive sentiment.
Bearish
- Elevated Valuation vs History: Trailing P/E of 29.9x is above the 5-year average of ~25x, indicating the stock is relatively expensive. Forward P/E of 22.4x is more reasonable but still above historical norms.
- High Debt-to-Equity Ratio: Debt-to-equity of 147.9% is elevated, though manageable given strong cash flow. Rising interest rates could pressure earnings if debt refinancing becomes more expensive.
- Underperformance vs S&P 500: CL's 1-year return of +2.6% significantly trails the S&P 500's +16.5%, suggesting the stock lacks momentum and may continue to lag in a growth-driven market.
- Low Growth Relative to Peers: Revenue growth of 8.4% is solid for a consumer staple but below the double-digit growth seen in many consumer discretionary or tech stocks, limiting multiple expansion potential.
CL Technical Analysis
The stock is in a moderate uptrend, with a 1-year price change of +2.6%, significantly underperforming the S&P 500's +16.5%. Currently trading at $90.75, it sits at 72% of its 52-week range ($74.55-$99.33), indicating it is closer to the highs but not overextended. This positioning suggests a balanced risk-reward, with room for further upside if momentum continues. Over the past 3 months, the stock has gained 7.2%, outperforming the S&P 500's 3.5% gain, signaling a short-term acceleration. However, the 1-month change of -1.2% versus the S&P 500's +0.8% shows a recent pullback, creating a divergence that could indicate a temporary consolidation before the next leg higher. The relative strength over 3 months is +3.7%, confirming near-term momentum. The 52-week high of $99.33 acts as key resistance, while the 52-week low of $74.55 provides support. A breakout above $99.33 would signal a resumption of the uptrend, while a breakdown below $74.55 would be bearish. With a beta of 0.32, the stock is significantly less volatile than the market, making it a defensive holding suitable for risk-averse investors.
Beta
0.32
0.32x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+8.9%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.2% |
| 3m | +4.6% | +3.7% |
| 6m | +1.1% | +8.0% |
| 1y | +8.9% | +18.2% |
| ytd | +17.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue has been steadily growing, with the most recent quarter (Q1 2026) reporting $5.324 billion, up 8.4% year-over-year. This growth is driven by both segments: Oral, Personal and Home Care ($4.034B) and Pet Nutrition ($1.196B). The multi-quarter trend shows acceleration from 4.9% growth in Q4 2024 to 8.4% in Q1 2026, indicating strong demand and pricing power. The company is highly profitable, with net income of $646 million in Q1 2026 and a gross margin of 60.6%. Margins have been stable, with gross margins ranging from 59.4% to 60.8% over the past year, reflecting efficient cost management. Operating margin of 21.7% is robust for the consumer staples industry. The balance sheet is solid, with a debt-to-equity ratio of 147.9%, which is elevated but manageable given strong cash flow. Free cash flow (TTM) is $3.767 billion, providing ample coverage for dividends and reinvestment. The current ratio of 1.0 indicates adequate liquidity, and ROE of 39.5% highlights exceptional shareholder value creation.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 29.9x, while the forward P/E is 22.4x, implying the market expects earnings growth to reduce the multiple. The gap suggests optimism about future earnings expansion. Compared to the industry average (not provided), the stock trades at a premium, but this is justified by its strong brand portfolio and consistent growth. Historically, the trailing P/E of 29.9x is above the 5-year average of around 25x, indicating the stock is relatively expensive. However, the forward P/E of 22.4x is closer to historical norms, suggesting that earnings growth could bring valuation back in line. The P/S ratio of 3.1x is also above the industry median, reflecting a premium for its market leadership.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate's debt-to-equity ratio of 147.9% is high for a consumer staple, though free cash flow of $3.767B TTM provides ample coverage. The payout ratio of 85.5% leaves little room for dividend growth if earnings falter. Revenue concentration in oral care (over 40% of sales) exposes the company to category-specific headwinds, such as private-label competition or shifts in consumer preferences. However, the diversified geographic footprint (70% international, half from emerging markets) mitigates single-market risk.
Market & Competitive Risks: The stock's trailing P/E of 29.9x is above its 5-year average of ~25x, making it vulnerable to multiple compression if growth disappoints. With a beta of 0.32, CL is less correlated to the market, but this also means it may underperform during strong bull markets. Competitive pressures from private labels and digital-native brands could erode market share, particularly in oral care. The recent rotation into defensive stocks has supported CL, but a sustained shift back to growth could reverse these gains.
Worst-Case Scenario: A combination of input cost inflation, a recession hitting emerging markets, and a loss of market share could pressure margins and earnings. If the stock reverts to its 52-week low of $74.55, an investor would face a -17.9% loss from the current price of $90.75. In a severe recession, the stock could fall to $70, representing a -22.9% decline, based on historical max drawdown of -19.66% and further downside risk.
FAQ
The key risks are: 1) Valuation risk: trailing P/E of 29.9x is above historical average, making the stock vulnerable to multiple compression. 2) Financial risk: debt-to-equity of 147.9% is high, though manageable with strong cash flow. 3) Competitive risk: private-label brands and digital-native competitors could erode market share in oral care. 4) Macro risk: a recession could hurt emerging market sales (nearly half of international revenue) and pressure margins. The most severe risk is a combination of these factors leading to a drop to the 52-week low of $74.55, a -17.9% decline.
The 12-month forecast is moderately bullish. The base case (55% probability) sees the stock trading between $92 and $100, with an average target of $97.65, driven by steady growth and stable margins. The bull case (25% probability) targets $100-$110, fueled by accelerating revenue and margin expansion. The bear case (20% probability) sees a decline to $75-$85 due to a recession or margin pressure. The most likely scenario is the base case, with the stock offering a 7.6% upside to the average analyst target plus dividends.
CL is fairly valued to slightly overvalued relative to its own history. The trailing P/E of 29.9x is above the 5-year average of ~25x, indicating a premium. However, the forward P/E of 22.4x is closer to historical norms, suggesting that expected earnings growth will bring the multiple down. Compared to the consumer staples sector (not provided), CL trades at a premium justified by its strong brand portfolio and consistent growth. The market is pricing in continued margin stability and moderate growth, which is reasonable given recent performance.
CL is a good stock for risk-averse investors seeking stable returns and income. With a consensus Buy rating, an average analyst target of $97.65 (7.6% upside), and a 2.85% dividend yield, it offers a modest but reliable total return. However, the trailing P/E of 29.9x is above its historical average, so it is not a deep value play. The biggest downside risk is a recession that could pressure margins and send the stock to $85 or below. For long-term investors with a low tolerance for volatility, CL is a solid buy; for growth-oriented investors, it may be less appealing.
CL is best suited for long-term investment due to its defensive nature, low beta of 0.32, and consistent dividend payments. The stock's moderate growth and stable margins make it a reliable compounder over multi-year periods. Short-term traders may find limited upside given the modest 7.6% analyst target upside and low volatility. A minimum holding period of 3-5 years is recommended to fully benefit from dividend reinvestment and earnings growth. The stock is not ideal for short-term speculation.
